Shares of Monte Rosa Therapeutics (GLUE) have gained 16.4% over the past four weeks to close the last trading session at $10.36, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17 indicates a potential upside of 64.1%.The mean estimate comprises six short-term price targets with a standard deviation of $2.45. While the lowest estimate of $15 indicates a 44.8% increase from the ...